Charles River Laboratories PE Ratio 2010-2023 | CRL
Current and historical p/e ratio for Charles River Laboratories (CRL) from 2010 to 2023. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Charles River Laboratories PE ratio as of April 25, 2024 is 21.39.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| Charles River Laboratories PE Ratio Historical Data |
| Date |
Stock Price |
TTM Net EPS |
PE Ratio |
| 2024-04-26 |
229.03 |
|
24.87 |
| 2023-12-31 |
236.40 |
$9.21 |
25.67 |
| 2023-09-30 |
195.98 |
$9.24 |
21.21 |
| 2023-06-30 |
210.25 |
$9.43 |
22.30 |
| 2023-03-31 |
201.82 |
$9.67 |
20.87 |
| 2022-12-31 |
217.90 |
$9.47 |
23.01 |
| 2022-09-30 |
196.80 |
$8.49 |
23.18 |
| 2022-06-30 |
213.97 |
$8.62 |
24.82 |
| 2022-03-31 |
283.97 |
$8.21 |
34.59 |
| 2021-12-31 |
376.78 |
$7.60 |
49.58 |
| 2021-09-30 |
412.67 |
$7.74 |
53.32 |
| 2021-06-30 |
369.92 |
$7.76 |
47.67 |
| 2021-03-31 |
289.83 |
$7.38 |
39.27 |
| 2020-12-31 |
249.86 |
$7.20 |
34.70 |
| 2020-09-30 |
226.45 |
$6.00 |
37.74 |
| 2020-06-30 |
174.35 |
$5.43 |
32.11 |
| 2020-03-31 |
126.21 |
$4.97 |
25.39 |
| 2019-12-31 |
152.76 |
$5.06 |
30.19 |
| 2019-09-30 |
132.37 |
$4.66 |
28.41 |
| 2019-06-30 |
141.90 |
$4.42 |
32.10 |
| 2019-03-31 |
145.25 |
$4.64 |
31.30 |
| 2018-12-31 |
113.18 |
$4.61 |
24.55 |
| 2018-09-30 |
134.54 |
$2.77 |
48.57 |
| 2018-06-30 |
112.26 |
$2.63 |
42.68 |
| 2018-03-31 |
106.74 |
$2.65 |
40.28 |
| 2017-12-31 |
109.45 |
$2.54 |
43.09 |
| 2017-09-30 |
108.02 |
$4.10 |
26.35 |
| 2017-06-30 |
101.15 |
$3.81 |
26.55 |
| 2017-03-31 |
89.95 |
$3.42 |
26.30 |
| 2016-12-31 |
76.19 |
$3.23 |
23.59 |
| 2016-09-30 |
83.34 |
$2.97 |
28.06 |
| 2016-06-30 |
82.44 |
$2.97 |
27.76 |
| 2016-03-31 |
75.94 |
$3.26 |
23.29 |
| 2015-12-31 |
80.39 |
$3.14 |
25.60 |
| 2015-09-30 |
63.52 |
$3.04 |
20.89 |
| 2015-06-30 |
70.34 |
$2.93 |
24.01 |
| 2015-03-31 |
79.29 |
$2.65 |
29.92 |
| 2014-12-31 |
63.64 |
$2.66 |
23.92 |
| 2014-09-30 |
59.74 |
$2.49 |
23.99 |
| 2014-06-30 |
53.52 |
$2.45 |
21.84 |
| 2014-03-31 |
60.34 |
$2.27 |
26.58 |
| 2013-12-31 |
53.04 |
$2.13 |
24.90 |
| 2013-09-30 |
46.26 |
$2.11 |
21.92 |
| 2013-06-30 |
41.03 |
$1.93 |
21.26 |
| 2013-03-31 |
44.27 |
$2.00 |
22.14 |
| 2012-12-31 |
37.47 |
$2.01 |
18.64 |
| 2012-09-30 |
39.60 |
$2.18 |
18.17 |
| 2012-06-30 |
32.76 |
$2.09 |
15.67 |
| 2012-03-31 |
36.09 |
$2.09 |
17.27 |
| 2011-12-31 |
27.33 |
$2.12 |
12.89 |
| 2011-09-30 |
28.62 |
$-4.47 |
0.00 |
| 2011-06-30 |
40.65 |
$-5.24 |
0.00 |
| 2011-03-31 |
38.38 |
$-5.65 |
0.00 |
| 2010-12-31 |
35.54 |
$-5.96 |
0.00 |
| 2010-09-30 |
33.15 |
$0.35 |
94.71 |
| 2010-06-30 |
34.21 |
$1.32 |
25.92 |
| 2010-03-31 |
39.31 |
$1.62 |
24.27 |
| 2009-12-31 |
33.69 |
$1.74 |
19.36 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical Services |
$11.735B |
$4.129B |
|
Charles River Laboratories International, Inc. is a full service, early-stage contract research organization. The company provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions globally accelerate their research and drug development efforts. The company has a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP. This helps support its clients from target identification through non-clinical development. Charles River also provides a line of products and services to support clients' manufacturing activities. Utilizing the company's broad portfolio of products and services, clients can create a more flexible drug development model, aiming cost reduction, productivity enhancement and increase in speed to market. Charles River currently has three reporting segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA) and Manufacturing Support.
|
